Status:
RECRUITING
Exploration of Predictive Markers of Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer
Lead Sponsor:
Geneplus-Beijing Co. Ltd.
Conditions:
Lung Cancer
Eligibility:
All Genders
18-80 years
Brief Summary
Neoadjuvant immunotherapy has become the standard perioperative treatment in lung cancer, but its effective predictive biomarkers are lacking. A small cohort reported that homologous recombination def...
Eligibility Criteria
Inclusion
- Stage II-IIIB NSCLC
- EGFR/ALK negative
- The subjects voluntarily joined the study, signed informed consent, had good compliance, and cooperated with follow-up
Exclusion
- A history of other malignancies within the past 5 years
- Patients with autoimmune disease are not suitable for PD1 monoclonal antibody therapy
Key Trial Info
Start Date :
June 19 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2025
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT05965557
Start Date
June 19 2023
End Date
December 1 2025
Last Update
September 4 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shanghai Chest Hospital
Shanghai, China